Larson Financial Group LLC Buys 788 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Larson Financial Group LLC lifted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 9.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 9,509 shares of the company’s stock after acquiring an additional 788 shares during the period. Larson Financial Group LLC’s holdings in Medpace were worth $3,159,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. R Squared Ltd bought a new position in Medpace during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. bought a new position in Medpace during the fourth quarter worth about $31,000. Stone House Investment Management LLC bought a new position in Medpace during the third quarter worth about $33,000. Ashton Thomas Securities LLC bought a new position in Medpace during the third quarter worth about $37,000. Finally, Jones Financial Companies Lllp lifted its stake in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after purchasing an additional 110 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 2.2 %

NASDAQ MEDP opened at $332.81 on Friday. The firm has a market cap of $10.14 billion, a price-to-earnings ratio of 26.35, a PEG ratio of 3.81 and a beta of 1.36. The company has a 50 day moving average of $341.10 and a 200-day moving average of $343.61. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Ratings Changes

Separately, Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Medpace has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.